Health claims debate
This article was originally published in The Tan Sheet
Executive Summary
Firms value authorized health claims "much more" than qualified claims "and will always prefer an authorized claim to an unauthorized one and only thereafter an unauthorized one to none at all," supplement marketers say in July 1 comments to FDA. Filed on behalf of Life Extension Foundation and Julian Whitaker, MD, by Washington, D.C-based Emord & Associates, comments respond to CSPI assertions that qualified claims eliminate incentive for authorized claims. On the contrary, the "two-tiered claim approach has the effect of encouraging research because rather than an all-or-nothing [significant scientific agreement] option, the fact that a qualified claim exists affords enough security to justify risking capital," comments state. Firms also maintain CSPI, in criticizing health claims, ignores Pearson rulings forcing FDA to favor disclaimers over speech suppression. CSPI filed comments in June (1"The Tan Sheet" June 9, 2003, p. 16)...
You may also be interested in...
Focus Group Testing For Health Claim Consumer Perception Advised By CSPI
FDA should use focus groups to determine whether consumers understand or are misled by health claims on foods and dietary supplements, according to comments submitted to FDA June 4 by the Center for Science in the Public Interest
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.